Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Xavier University Of Louisiana has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners, meaning each action is being reviewed by a different person. The subject matter is split between 2 distinct art units.
BAUER, BRIANNA LEE is the busiest examiner for the university, currently responsible for 1 pending office action. Since there are 3 distinct examiners for the 3 pending actions, the workload is evenly spread. The involvement of 2 distinct art units suggests that the university's biotechnology filings are categorized into different technical niches within the patent office. This variety in both examiners and art units requires the university to manage separate prosecution tracks, each potentially subject to different examination nuances within the biotechnology sector. Practitioners should ensure that their strategies are tailored to the specific feedback of each examiner across these different specialized units.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAUER, BRIANNA LEE | 1 | 100.0% | +0.0% |
| DEKARSKE, MADELINE MCGUIRE | 1 | 0.0% | +0.0% |
| MCANANY, JOHN D | 1 | 67.2% | +43.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17771391 | PROTEIN KINASE INHIBITORS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISEASES | MCANANY, JOHN D | 26d overdue |
| 18347724 | PHENYL UNSATURATED KETONES AS HUMAN FACTOR XIIIA INHIBITORS FOR TREATMENT OF THROMBOEMBOLIC DISEASES | DEKARSKE, MADELINE MCGUIRE | 13d |
| 18891013 | SULFONATED AND PHOSPHORYLATED AROMATIC MOLECULES | BAUER, BRIANNA LEE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17771391 | PROTEIN KINASE INHIBITORS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISEASES | MCANANY, JOHN D | 26d overdue |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18891013 | SULFONATED AND PHOSPHORYLATED AROMATIC MOLECULES | BAUER, BRIANNA LEE | — | §103§112 | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18347724 | PHENYL UNSATURATED KETONES AS HUMAN FACTOR XIIIA INHIBITORS FOR TREATMENT OF THROMBOEMBOLIC DISEASES | DEKARSKE, MADELINE MCGUIRE | 1622 | §102§103 | Final Rejection | 13d | Pending | Jul 06, 2023 |
| 17771391 | PROTEIN KINASE INHIBITORS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISEASES | MCANANY, JOHN D | 1625 | §102§103 | Final Rejection | 26d overdue | Pending | Apr 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial